WO2012018761A3 - Méthode de traitement de cancers induits par les androgènes - Google Patents

Méthode de traitement de cancers induits par les androgènes Download PDF

Info

Publication number
WO2012018761A3
WO2012018761A3 PCT/US2011/046193 US2011046193W WO2012018761A3 WO 2012018761 A3 WO2012018761 A3 WO 2012018761A3 US 2011046193 W US2011046193 W US 2011046193W WO 2012018761 A3 WO2012018761 A3 WO 2012018761A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgen
treatment
mediated cancers
mediated
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/046193
Other languages
English (en)
Other versions
WO2012018761A2 (fr
Inventor
Barry Scott Brand
Daniel Joesph Burch
Ranga Krishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CeneRx Biopharma Inc
Original Assignee
CeneRx Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CeneRx Biopharma Inc filed Critical CeneRx Biopharma Inc
Publication of WO2012018761A2 publication Critical patent/WO2012018761A2/fr
Publication of WO2012018761A3 publication Critical patent/WO2012018761A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement de cancers induits par les androgènes. Ces méthodes consistent à administrer une quantité thérapeutiquement efficace d'un produit pharmaceutique comprenant au moins un inhibiteur sélectif et réversible de la monoamine oxydase A.
PCT/US2011/046193 2010-08-05 2011-08-02 Méthode de traitement de cancers induits par les androgènes Ceased WO2012018761A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37094210P 2010-08-05 2010-08-05
US61/370,942 2010-08-05

Publications (2)

Publication Number Publication Date
WO2012018761A2 WO2012018761A2 (fr) 2012-02-09
WO2012018761A3 true WO2012018761A3 (fr) 2012-05-24

Family

ID=45560015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046193 Ceased WO2012018761A2 (fr) 2010-08-05 2011-08-02 Méthode de traitement de cancers induits par les androgènes

Country Status (1)

Country Link
WO (1) WO2012018761A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012109A2 (fr) 2007-07-13 2009-01-22 Emory University Composes contenant de la cyanine utiles dans l'imagerie et le traitement du cancer
EP2736506B1 (fr) * 2011-07-26 2018-09-05 University Of Southern California Inhibiteurs de monoamine oxydase et procédés pour le traitement et le diagnostic du cancer de la prostate
US9675620B2 (en) 2011-07-26 2017-06-13 University Of Southern California MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
CN103040836A (zh) * 2013-01-11 2013-04-17 吴伯阳 吗氯贝胺的抗前列腺癌用途及其药物制剂
ES2898681T3 (es) * 2017-01-23 2022-03-08 Roussy Inst Gustave Amplificadores del canibalismo celular para la utilización para sensibilizar tumores a la terapia de radiación
WO2019145363A1 (fr) * 2018-01-23 2019-08-01 Institut Gustave-Roussy Utilisation de minaprine pour réduire la croissance tumorale
KR20260040871A (ko) * 2024-09-19 2026-03-26 이화여자대학교 산학협력단 피라지노 카바졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176469A1 (en) * 2000-07-27 2004-09-09 Thomas Nadackal Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176469A1 (en) * 2000-07-27 2004-09-09 Thomas Nadackal Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HONGJUAN ZHAO ET AL.: "Inhibition of monoamine oxidase A promotes secretory differentiation is basal prostatic epithelial cells.", DIFFERENTIATION., vol. 76, no. 7, September 2008 (2008-09-01), pages 820 - 830, XP026772234, DOI: doi:10.1111/j.1432-0436.2007.00263.x *
LAWRENCE TRUE ET AL.: "A molecular correlate to the Gleason grading system f or prostate adenocarcinoma.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITIED STATES OF AMERICA, vol. 103, no. 29, 18 July 2006 (2006-07-18), pages 10991 - 10996 *
VINCENT FLAMAND ET AL.: "Targeting monoamine oxidase A in advanced prostate cancer.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY., vol. 136, no. 11, 4 March 2010 (2010-03-04), pages 1761 - 1771, XP019849130 *

Also Published As

Publication number Publication date
WO2012018761A2 (fr) 2012-02-09

Similar Documents

Publication Publication Date Title
WO2012103059A3 (fr) Inhibiteurs de bcl-2/bcl-xl et méthodes thérapeutiques les utilisant
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
EP4279087A3 (fr) Inhibiteurs de pd-1/pd-l1 pour le traitement du cancer
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
MX2010006823A (es) Metodos para el tratamiento de la gota.
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
WO2010071846A3 (fr) Composés pour traiter des états neuropsychiatriques
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
WO2010077589A3 (fr) Inhibiteurs de stat3 et méthodes thérapeutiques les utilisant
EP4013485A4 (fr) Procédés et dispositifs de traitement par neurostimulation transdermique
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
WO2011009039A3 (fr) Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
WO2012042224A3 (fr) Composition pharmaceutique
WO2010091384A3 (fr) Inhibiteurs de la cadhérine-11 et méthodes d'utilisation associées
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
HK1219434A1 (zh) 用於加速斑块消退的组合物和治疗方法
EP2012807A4 (fr) Composition pharmaceutique d'entérosorbant et de prébiotiques, formes galéniques et procédé pour la prévention et le traitement de troubles gastrointestinaux
WO2012040082A3 (fr) Compositions pharmaceutiques solides antidiabétiques
WO2011130692A3 (fr) Inhibiteurs du stress oxydatif induit par les androgènes
WO2012024670A3 (fr) Composition et méthodes de traitement du glioblastome
WO2012018759A3 (fr) Méthode de traitement de cancers induits par les androgènes
WO2012031118A3 (fr) Inhibiteurs du complexe de promotion de l'anaphase pouvant pénétrer dans des cellules
WO2016126572A3 (fr) Inhibiteurs de la glucosylcéramide synthase et méthodes thérapeutiques les utilisant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815154

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815154

Country of ref document: EP

Kind code of ref document: A2